Molecular mechanisms of cachexia in chronic disease

References

• Evans WJ, Morley JE, Argiles J et al. Cachexia: a new definition. Clin. Nutr.27(6), 793–799 (2008).
   PubMed Web of Science ®Google Scholar
• Argiles JM, Anker SD, Evans WJ et al. Consensus on cachexia definitions. J. Am. Med. Dir. Assoc.11(4), 229–230 (2010).
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol.12(5), 489–495 (2011).
   PubMed Web of Science ®Google Scholar
• Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care11(4), 400–407 (2008).
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argiles J et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin. Nutr.29(2), 154–159 (2010).
   PubMed Web of Science ®Google Scholar
• Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur. Respir. J.31(3), 492–501 (2008).
   PubMed Web of Science ®Google Scholar
• Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr. Opin. Support Palliat. Care3(4), 263–268 (2009).
   PubMedGoogle Scholar
• Tisdale MJ. Mechanisms of cancer cachexia. Physiol. Rev.89(2), 381–410 (2009).
   PubMed Web of Science ®Google Scholar
• Laviano A, Inui A, Marks DL et al. Neural control of the anorexia-cachexia syndrome. Am. J. Physiol. Endocrinol. Metab.295(5), E1000–E1008 (2008).
   PubMed Web of Science ®Google Scholar
• Garfield AS, Lam DD, Marston OJ, Przydzial MJ, Heisler LK. Role of central melanocortin pathways in energy homeostasis. Trends Endocrinol. Metab.20(5), 203–215 (2009).
   PubMed Web of Science ®Google Scholar
• Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev.31(4), 506–543 (2010).
   PubMed Web of Science ®Google Scholar
• Krasnow SM, Marks DL. Neuropeptides in the pathophysiology and treatment of cachexia. Curr. Opin. Support Palliat. Care4(4), 266–271 (2010).
   PubMedGoogle Scholar
• Tolle V, Low MJ. In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice. Diabetes57(1), 86–94 (2008).
   PubMedGoogle Scholar
• Bagnol D, Lu XY, Kaelin CB et al. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J. Neurosci.19(18), RC26 (1999).
   PubMedGoogle Scholar
• Huszar D, Lynch CA, Fairchild-Huntress V et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell88(1), 131–141 (1997).
   PubMed Web of Science ®Google Scholar
• Tung YC, Rimmington D, O’Rahilly S, Coll AP. Pro-opiomelanocortin modulates the thermogenic and physical activity responses to high-fat feeding and markedly influences dietary fat preference. Endocrinology148(11), 5331–5338 (2007).
   PubMed Web of Science ®Google Scholar
• Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science310(5748), 683–685 (2005).
   PubMed Web of Science ®Google Scholar
• Appleyard SM, Bailey TW, Doyle MW et al. Proopiomelanocortin neurons in nucleus tractus solitarius are activated by visceral afferents: regulation by cholecystokinin and opioids. J. Neurosci.25(14), 3578–3585 (2005).
   PubMedGoogle Scholar
• Fioramonti X, Contie S, Song Z, Routh VH, Lorsignol A, Penicaud L. Characterization of glucosensing neuron subpopulations in the arcuate nucleus: integration in neuropeptide Y and pro-opio melanocortin networks? Diabetes56(5), 1219–1227 (2007).
   PubMedGoogle Scholar
• Parton LE, Ye CP, Coppari R et al. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature449(7159), 228–232 (2007).
   PubMed Web of Science ®Google Scholar
• Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J. Clin. Invest.115(6), 1659–1665 (2005).
   PubMed Web of Science ®Google Scholar
• Marks DL, Butler AA, Turner R, Brookhart G, Cone RD. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology144(4), 1513–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Sartin JL, Marks DL, McMahon CD et al. Central role of the melanocortin-4 receptors in appetite regulation after endotoxin. J. Anim. Sci.86(10), 2557–2567 (2008).
   PubMedGoogle Scholar
• Joppa MA, Gogas KR, Foster AC, Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides28(3), 636–642 (2007).
   PubMed Web of Science ®Google Scholar
• Scarlett JM, Bowe DD, Zhu X, Batra AK, Grant WF, Marks DL. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J. Endocrinol.206(1), 121–130 (2010).
   PubMedGoogle Scholar
• Cheung WW, Kuo HJ, Markison S et al. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J. Am. Soc. Nephrol.18(9), 2517–2524 (2007).
   PubMed Web of Science ®Google Scholar
• Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol.4(11), 686–694 (2003).
   PubMed Web of Science ®Google Scholar
• Chance WT, Xiao C, Dayal R, Sheriff S. Alteration of NPY and Y1 receptor in dorsomedial and ventromedial areas of hypothalamus in anorectic tumor-bearing rats. Peptides28(2), 295–301 (2007).
   PubMedGoogle Scholar
• Grossberg AJ, Scarlett JM, Marks DL. Hypothalamic mechanisms in cachexia. Physiol. Behav.100(5), 478–489 (2010).
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski PP, Clark AL et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J.20(9), 683–693 (1999).
   PubMed Web of Science ®Google Scholar
• Arruda AP, Milanski M, Romanatto T et al. Hypothalamic actions of tumor necrosis factor α provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology151(2), 683–694 (2010).
   PubMedGoogle Scholar
• Deboer MD, Scarlett JM, Levasseur PR, Grant WF, Marks DL. Administration of IL-1 β to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract. Peptides30(2), 210–218 (2009).
   PubMed Web of Science ®Google Scholar
• Johnen H, Lin S, Kuffner T et al. Tumor-induced anorexia and weight loss are mediated by the TGF- β superfamily cytokine MIC-1. Nat. Med.13(11), 1333–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Skipworth RJ, Deans DA, Tan BH et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br. J. Cancer102(4), 665–672 (2010).
   PubMed Web of Science ®Google Scholar
• Gayle D, Ilyin SE, Flynn MC, Plata-Salaman CR. Lipopolysaccharide (LPS)- and muramyl dipeptide (MDP)-induced anorexia during refeeding following acute fasting: characterization of brain cytokine and neuropeptide systems mRNAs. Brain Res.795(1–2), 77–86 (1998).
   PubMedGoogle Scholar
• Utsuyama M, Hirokawa K. Differential expression of various cytokine receptors in the brain after stimulation with LPS in young and old mice. Exp. Gerontol.37(2–3), 411–420 (2002).
   PubMed Web of Science ®Google Scholar
• Grossberg AJ, Scarlett JM, Zhu X et al. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology151(2), 606–616 (2010).
   PubMedGoogle Scholar
• Dallaporta M, Pecchi E, Jacques C et al. c-Fos immunoreactivity induced by intraperitoneal LPS administration is reduced in the brain of mice lacking the microsomal prostaglandin E synthase-1 (mPGES-1). Brain Behav. Immun.21(8), 1109–1121 (2007).
   PubMedGoogle Scholar
• Pecchi E, Dallaporta M, Jean A, Thirion S, Troadec JD. mPGES-1 knock-out mice are resistant to cancer-induced anorexia despite the absence of central mPGES-1 up-regulation in wild-type anorexic mice. J. Neuroimmunol.199(1–2), 104–114 (2008).
   PubMedGoogle Scholar
• Heisler LK, Jobst EE, Sutton GM et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron51(2), 239–249 (2006).
   PubMed Web of Science ®Google Scholar
• Cangiano C, Cascino A, Ceci F et al. Plasma and CSF tryptophan in cancer anorexia. J. Neural. Transm. Gen. Sect.81(3), 225–233 (1990).
   PubMedGoogle Scholar
• Laviano A, Cangiano C, Preziosa I et al. Plasma tryptophan levels and anorexia in liver cirrhosis. Int. J. Eat. Disord.21(2), 181–186 (1997).
   PubMed Web of Science ®Google Scholar
• Laviano A, Meguid MM, Cascino A, Molfino A, Rossi Fanelli F. Tryptophan in wasting diseases: at the crossing between immune function and behaviour. Curr. Opin. Clin. Nutr. Metab. Care12(4), 392–397 (2009).
   PubMed Web of Science ®Google Scholar
• Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc. Natl Acad. Sci. USA100(22), 12624–12629 (2003).
   PubMed Web of Science ®Google Scholar
• Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM. Adipokines in patients with cancer anorexia and cachexia. J. Investig. Med.58(3), 554–559 (2010).
   PubMed Web of Science ®Google Scholar
• Nakajima TE, Yamada Y, Hamano T et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J. Gastroenterol.44(7), 685–690 (2009).
   PubMed Web of Science ®Google Scholar
• Itoh T, Nagaya N, Yoshikawa M et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.170(8), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Xin X, Ren AJ, Zheng X et al. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides30(12), 2281–2285 (2009).
   PubMedGoogle Scholar
• Garcia JM, Garcia-Touza M, Hijazi RA et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab.90(5), 2920–2926 (2005).
   PubMed Web of Science ®Google Scholar
• Deboer MD, Zhu XX, Levasseur P et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology148(6), 3004–3012 (2007).
   PubMed Web of Science ®Google Scholar
• Deboer MD, Zhu X, Levasseur PR et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology149(2), 827–835 (2008).
   PubMed Web of Science ®Google Scholar
• Ruud J, Blomqvist A. Identification of rat brainstem neuronal structures activated during cancer-induced anorexia. J. Comp. Neurol.504(3), 275–286 (2007).
   PubMedGoogle Scholar
• Gaykema RP, Daniels TE, Shapiro NJ, Thacker GC, Park SM, Goehler LE. Immune challenge and satiety-related activation of both distinct and overlapping neuronal populations in the brainstem indicate parallel pathways for viscerosensory signaling. Brain Res.1294, 61–79 (2009).
   PubMedGoogle Scholar
• Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest.117(2), 289–296 (2007).
   PubMed Web of Science ®Google Scholar
• Nogueiras R, Wiedmer P, Perez-Tilve D et al. The central melanocortin system directly controls peripheral lipid metabolism. J. Clin. Invest.117(11), 3475–3488 (2007).
   PubMed Web of Science ®Google Scholar
• Rossi J, Balthasar N, Olson D et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab.13(2), 195–204 (2011).
   PubMed Web of Science ®Google Scholar
• Cypess AM, Lehman S, Williams G et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med.360(15), 1509–1517 (2009).
   PubMed Web of Science ®Google Scholar
• Virtanen KA, Lidell ME, Orava J et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med.360(15), 1518–1525 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kerman IA, Laque A et al. Leptin-receptor-expressing neurons in the dorsomedial hypothalamus and median preoptic area regulate sympathetic brown adipose tissue circuits. J. Neurosci.31(5), 1873–1884 (2011).
   PubMed Web of Science ®Google Scholar
• Voss-Andreae A, Murphy JG, Ellacott KL et al. Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. Endocrinology148(4), 1550–1560 (2007).
   PubMed Web of Science ®Google Scholar
• Brito MN, Brito NA, Baro DJ, Song CK, Bartness TJ. Differential activation of the sympathetic innervation of adipose tissues by melanocortin receptor stimulation. Endocrinology148(11), 5339–5347 (2007).
   PubMedGoogle Scholar
• Hargrove JL, Heinz G, Heinz O. Modeling transitions in body composition: the approach to steady state for anthropometric measures and physiological functions in the Minnesota human starvation study. Dyn. Med.7, 16 (2008).
   PubMedGoogle Scholar
• Haas V, Onur S, Paul T et al. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. Am. J. Clin. Nutr.81(4), 889–896 (2005).
   PubMedGoogle Scholar
• Sergi G, Coin A, Marin S et al. Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir. Med.100(11), 1918–1924 (2006).
   PubMed Web of Science ®Google Scholar
• Cao DX, Wu GH, Zhang B et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin. Nutr.29(1), 72–77 (2010).
   PubMed Web of Science ®Google Scholar
• Riggio O, Angeloni S, Ciuffa L et al. Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. Clin. Nutr.22(6), 553–559 (2003).
   PubMedGoogle Scholar
• Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br. J. Cancer90(5), 996–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog. Brain Res.153, 209–235 (2006).
   PubMedGoogle Scholar
• Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care – correlations with food intake, metabolism, exercise capacity, and hormones. Cancer103(10), 2189–2198 (2005).
   PubMed Web of Science ®Google Scholar
• Vanhorebeek I, Langouche L, Van Den Berghe G. Endocrine aspects of acute and prolonged critical illness. Nat. Clin. Pract. Endocrinol. Metab.2(1), 20–31 (2006).
   PubMedGoogle Scholar
• Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by β-adrenergic receptor blocker therapy in patients with chronic heart failure. J. Card. Fail.9(6), 464–468 (2003).
   PubMed Web of Science ®Google Scholar
• Muller MJ, Bottcher J, Selberg O et al. Hypermetabolism in clinically stable patients with liver cirrhosis. Am. J. Clin. Nutr.69(6), 1194–1201 (1999).
   PubMed Web of Science ®Google Scholar
• Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with β blockers: a pilot study. Int. J. Cardiol.106(3), 319–322 (2006).
   PubMed Web of Science ®Google Scholar
• Dumas JF, Goupille C, Julienne CM et al. Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis. J. Hepatol.54(2), 320–327 (2011).
   PubMedGoogle Scholar
• Bevilacqua L, Seifert EL, Estey C, Gerrits MF, Harper ME. Absence of uncoupling protein-3 leads to greater activation of an adenine nucleotide translocase-mediated proton conductance in skeletal muscle mitochondria from calorie restricted mice. Biochim. Biophys. Acta1797(8), 1389–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Constantinou C, Fontes De Oliveira CC, Mintzopoulos D et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med.27(1), 15–24 (2011).
   PubMed Web of Science ®Google Scholar
• White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW, Carson JA. Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am. J. Physiol. Regul. Integr. Comp. Physiol.300(2), R201–R211 (2011).
   Google Scholar
• Sanders PM, Tisdale MJ. Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett.212(1), 71–81 (2004).
   PubMed Web of Science ®Google Scholar
• Virtanen KA, Nuutila P. Brown adipose tissue in humans. Curr. Opin. Lipidol.22(1), 49–54 (2011).
   PubMedGoogle Scholar
• Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res.60(9), 2405–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Bing C, Russell ST, Beckett EE et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br. J. Cancer86(4), 612–618 (2002).
   PubMed Web of Science ®Google Scholar
• Busquets S, Almendro V, Barreiro E, Figueras M, Argiles JM, Lopez-Soriano FJ. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett.579(3), 717–722 (2005).
   PubMed Web of Science ®Google Scholar
• Minnaard R, Schrauwen P, Schaart G, Hesselink MK. UCP3 in muscle wasting, a role in modulating lipotoxicity? FEBS Lett.580(22), 5172–5176 (2006).
   PubMedGoogle Scholar
• Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab.2(2), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Busquets S, Garcia-Martinez C, Olivan M, Barreiro E, Lopez-Soriano FJ, Argiles JM. Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: a role in muscle wasting? Biochim. Biophys. Acta1760(2), 253–258 (2006).
   PubMedGoogle Scholar
• Dejong CH, Busquets S, Moses AG et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep.14(1), 257–263 (2005).
   PubMed Web of Science ®Google Scholar
• Collins P, Bing C, Mcculloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br. J. Cancer86(3), 372–375 (2002).
   PubMed Web of Science ®Google Scholar
• Muller MJ, Bosy-Westphal A, Kutzner D, Heller M. Metabolically active components of fat-free mass and resting energy expenditure in humans: recent lessons from imaging technologies. Obes. Rev.3(2), 113–122 (2002).
   PubMedGoogle Scholar
• Kushner I, Rzewnicki DL. The acute phase response: general aspects. Baillieres Clin. Rheumatol.8(3), 513–530 (1994).
   PubMedGoogle Scholar
• Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr. Opin. Support Palliat. Care2(4), 267–274 (2008).
   PubMedGoogle Scholar
• Mcmillan DC, Slater C, Preston T, Falconer JS, Fearon KC. Simultaneous measurement of albumin and fibrinogen synthetic rates in normal fasted subjects. Nutrition12(9), 602–607 (1996).
   PubMed Web of Science ®Google Scholar
• Bonetto A, Aydogdu T, Kunzevitzky N et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One6(7), e22538 (2011).
   PubMed Web of Science ®Google Scholar
• Watchorn TM, Waddell I, Dowidar N, Ross JA. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(κ)B and STAT3. FASEB J.15(3), 562–564 (2001).
   PubMedGoogle Scholar
• Zhang L, Du J, Hu Z et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J. Am. Soc. Nephrol.20(3), 604–612 (2009).
   PubMedGoogle Scholar
• Martignoni ME, Dimitriu C, Bachmann J et al. Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol. Rep.21(2), 363–369 (2009).
   PubMed Web of Science ®Google Scholar
• Berriel Diaz M, Krones-Herzig A, Metzger D et al. Nuclear receptor cofactor receptor interacting protein 140 controls hepatic triglyceride metabolism during wasting in mice. Hepatology48(3), 782–791 (2008).
   PubMedGoogle Scholar
• Herzig S, Hedrick S, Morantte I, Koo SH, Galimi F, Montminy M. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ. Nature426(6963), 190–193 (2003).
   PubMedGoogle Scholar
• Yoon JC, Puigserver P, Chen G et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature413(6852), 131–138 (2001).
   PubMed Web of Science ®Google Scholar
• Viollet B, Horman S, Leclerc J et al. AMPK inhibition in health and disease. Crit. Rev. Biochem. Mol. Biol.45(4), 276–295 (2010).
   PubMed Web of Science ®Google Scholar
• Viollet B, Foretz M, Guigas B et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol.574(Pt 1), 41–53 (2006).
   PubMed Web of Science ®Google Scholar
• Kukidome D, Nishikawa T, Sonoda K et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes55(1), 120–127 (2006).
   PubMed Web of Science ®Google Scholar
• Iwabu M, Yamauchi T, Okada-Iwabu M et al. Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca(2+) and AMPK/SIRT1. Nature464(7293), 1313–1319 (2010).
   PubMed Web of Science ®Google Scholar
• Koo SH, Satoh H, Herzig S et al. PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3. Nat. Med.10(5), 530–534 (2004).
   PubMed Web of Science ®Google Scholar
• Liu C, Lin JD. PGC-1 coactivators in the control of energy metabolism. Acta Biochim. Biophys. Sin. (Shanghai)43(4), 248–257 (2011).
   PubMed Web of Science ®Google Scholar
• Puigserver P, Rhee J, Lin J et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol. Cell8(5), 971–982 (2001).
   PubMed Web of Science ®Google Scholar
• Takabatake N, Nakamura H, Abe S et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.161(4 Pt 1), 1179–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Raguso CA, Luthy C. Nutritional status in chronic obstructive pulmonary disease: role of hypoxia. Nutrition27(2), 138–143 (2011).
   PubMedGoogle Scholar
• Swallow EB, Reyes D, Hopkinson NS et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax62(2), 115–120 (2007).
   PubMed Web of Science ®Google Scholar
• Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol.300(6), H1973–H1982 (2011).
   Web of Science ®Google Scholar
• Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin. Infect. Dis.36(Suppl. 2), S69–S78 (2003).
   PubMed Web of Science ®Google Scholar
• Baltgalvis KA, Berger FG, Pena MM, Mark Davis J, White JP, Carson JA. Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice. J. Appl. Physiol.109(4), 1155–1161 (2010).
   PubMed Web of Science ®Google Scholar
• Toledo M, Busquets S, Sirisi S et al. Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol. Rep.25(1), 189–193 (2011).
   PubMed Web of Science ®Google Scholar
• Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol.37(10), 1974–1984 (2005).
   PubMed Web of Science ®Google Scholar
• Aguilar V, Alliouachene S, Sotiropoulos A et al. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab.5(6), 476–487 (2007).
   PubMedGoogle Scholar
• Drummond MJ, Dreyer HC, Fry CS, Glynn EL, Rasmussen BB. Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. J. Appl. Physiol.106(4), 1374–1384 (2009).
   PubMed Web of Science ®Google Scholar
• Mieulet V, Roceri M, Espeillac C et al. S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am. J. Physiol. Cell Physiol.293(2), C712–C722 (2007).
   PubMed Web of Science ®Google Scholar
• Shahbazian D, Roux PP, Mieulet V et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J.25(12), 2781–2791 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J.20(16), 4370–4379 (2001).
   PubMed Web of Science ®Google Scholar
• Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol.21(2), 209–218 (2009).
   PubMed Web of Science ®Google Scholar
• Toth MJ, Ward K, Van Der Velden J et al. Chronic heart failure reduces Akt phosphorylation in human skeletal muscle: relationship to muscle size and function. J. Appl. Physiol.110(4), 892–900 (2011).
   PubMedGoogle Scholar
• Zhou X, Wang JL, Lu J et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell142(4), 531–543 (2010).
   PubMed Web of Science ®Google Scholar
• Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun.391(3), 1548–1554 (2010).
   PubMed Web of Science ®Google Scholar
• Sartori R, Milan G, Patron M et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol.296(6), C1248–C1257 (2009).
   PubMedGoogle Scholar
• Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol.296(6), C1258–C1270 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao J, Brault JJ, Schild A et al. FOXO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab.6(6), 472–483 (2007).
   PubMed Web of Science ®Google Scholar
• Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr.129(Suppl. 1), S227–S237 (1999).
   PubMed Web of Science ®Google Scholar
• Dahlmann B. Role of proteasomes in disease. BMC Biochem.8(Suppl. 1), S3 (2007).
   Web of Science ®Google Scholar
• Lecker SH, Jagoe RT, Gilbert A et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J.18(1), 39–51 (2004).
   PubMed Web of Science ®Google Scholar
• Cong H, Sun L, Liu C, Tien P. Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther.22(3), 313–324 (2011).
   PubMedGoogle Scholar
• Eddins MJ, Marblestone JG, Suresh Kumar KG et al. Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy. Cell Biochem. Biophys.60(1–2), 113–118 (2011).
   PubMedGoogle Scholar
• Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS, Lang CH. AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. Am. J. Physiol. Endocrinol. Metab.292(6), E1555–E1567 (2007).
   PubMed Web of Science ®Google Scholar
• Sandri M, Sandri C, Gilbert A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell117(3), 399–412 (2004).
   PubMed Web of Science ®Google Scholar
• Mcclung JM, Judge AR, Powers SK, Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am. J. Physiol. Cell Physiol.298(3), C542–C549 (2010).
   PubMed Web of Science ®Google Scholar
• Agusti AG, Sauleda J, Miralles C et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.166(4), 485–489 (2002).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Sumi T, Nobeyama H et al. Multiple organ failure of tumor-bearing rabbits in cancer cachexia is caused by apoptosis of normal organ cells. Int. J. Oncol.34(1), 61–67 (2009).
   PubMedGoogle Scholar
• Argiles JM, Lopez-Soriano FJ, Busquets S. Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int. J. Biochem. Cell Biol.40(9), 1674–1678 (2008).
   PubMedGoogle Scholar
• Du J, Wang X, Miereles C et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Invest.113(1), 115–123 (2004).
   PubMed Web of Science ®Google Scholar
• Busquets S, Deans C, Figueras M et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin. Nutr.26(5), 614–618 (2007).
   PubMedGoogle Scholar
• Mcghee NK, Jefferson LS, Kimball SR. Elevated corticosterone associated with food deprivation upregulates expression in rat skeletal muscle of the mTORC1 repressor, REDD1. J. Nutr.139(5), 828–834 (2009).
   PubMed Web of Science ®Google Scholar
• Kuma A, Hatano M, Matsui M et al. The role of autophagy during the early neonatal starvation period. Nature432(7020), 1032–1036 (2004).
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Hartl FU. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science310(5756), 1960–1963 (2005).
   PubMed Web of Science ®Google Scholar
• Baracos VE, Devivo C, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol.268(5 Pt 1), E996–E1006 (1995).
   Google Scholar
• Criollo A, Senovilla L, Authier H et al. The IKK complex contributes to the induction of autophagy. EMBO J.29(3), 619–631 (2010).
   PubMed Web of Science ®Google Scholar
• Paul PK, Gupta SK, Bhatnagar S et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol.191(7), 1395–1411 (2010).
   PubMed Web of Science ®Google Scholar
• Paul PK, Kumar A. TRAF6 coordinates the activation of autophagy and ubiquitin-proteasome systems in atrophying skeletal muscle. Autophagy7(5), 555–556 (2011).
   PubMed Web of Science ®Google Scholar
• Rhoads MG, Kandarian SC, Pacelli F, Doglietto GB, Bossola M. Expression of NF-κ B and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer46(1), 191–197 (2010).
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Mittal A, Gupta SK, Kumar A. TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell Physiol. doi:10.1002/jcp.22821 (2011) (Epub ahead of print).
   Google Scholar
• Sciorati C, Touvier T, Buono R et al. Necdin is expressed in cachectic skeletal muscle to protect fibers from tumor-induced wasting. J. Cell Sci.122(Pt 8), 1119–1125 (2009).
   PubMedGoogle Scholar
• Barreiro E, De La Puente B, Busquets S, Lopez-Soriano FJ, Gea J, Argiles JM. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett.579(7), 1646–1652 (2005).
   PubMed Web of Science ®Google Scholar
• Fuster G, Busquets S, Ametller E et al. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of β 2-adrenergic agonists. Cancer Res.67(13), 6512–6519 (2007).
   PubMed Web of Science ®Google Scholar
• Guarnier FA, Cecchini AL, Suzukawa AA et al. Time course of skeletal muscle loss and oxidative stress in rats with Walker 256 solid tumor. Muscle Nerve42(6), 950–958 (2010).
   PubMedGoogle Scholar
• Mortensen OH, Frandsen L, Schjerling P, Nishimura E, Grunnet N. PGC-1α and PGC-1β have both similar and distinct effects on myofiber switching toward an oxidative phenotype. Am. J. Physiol. Endocrinol. Metab.291(4), E807–E816 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez M, Lelliott CJ, Tovar S et al. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes55(5), 1327–1336 (2006).
   PubMed Web of Science ®Google Scholar
• Cha SH, Rodgers JT, Puigserver P, Chohnan S, Lane MD. Hypothalamic malonyl-CoA triggers mitochondrial biogenesis and oxidative gene expression in skeletal muscle: role of PGC-1α. Proc. Natl Acad. Sci. USA103(42), 15410–15415 (2006).
   PubMedGoogle Scholar
• Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int.74(2), 180–186 (2008).
   PubMed Web of Science ®Google Scholar
• Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P, Hofbauer KG. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J. Pharmacol. Exp. Ther.317(2), 771–777 (2006).
   PubMed Web of Science ®Google Scholar
• O’Neill ED, Wilding JP, Kahn CR et al. Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. Age (Dordr.)32(2), 209–222 (2010).
   PubMedGoogle Scholar
• Holt RI, Jones JS, Baker AJ, Buchanan CR, Miell JP. The effect of short stature, portal hypertension, and cholestasis on growth hormone resistance in children with liver disease. J. Clin. Endocrinol. Metab.84(9), 3277–3282 (1999).
   PubMedGoogle Scholar
• Mak RH, Cheung WW, Roberts CT Jr. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Growth Horm. IGF Res.18(1), 17–25 (2008).
   PubMedGoogle Scholar
• Yang SY, Hoy M, Fuller B, Sales KM, Seifalian AM, Winslet MC. Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways. Lab Invest.90(3), 391–401 (2010).
   PubMedGoogle Scholar
• Cassano M, Quattrocelli M, Crippa S, Perini I, Ronzoni F, Sampaolesi M. Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass. J. Muscle Res. Cell Motil.30(7–8), 243–253 (2009).
   PubMedGoogle Scholar
• Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, Costelli P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One5(10), e13604 (2010).
   PubMed Web of Science ®Google Scholar
• Lopez-Menduina M, Martin AI, Castillero E, Villanua MA, Lopez-Calderon A. Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3. Am. J. Physiol. Regul. Integr. Comp. Physiol.299(2), R541–R551 (2010).
   Google Scholar
• Stitt TN, Drujan D, Clarke BA et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell14(3), 395–403 (2004).
   PubMed Web of Science ®Google Scholar
• Paddon-Jones D, Sheffield-Moore M, Cree MG et al. Atrophy and impaired muscle protein synthesis during prolonged inactivity and stress. J. Clin. Endocrinol. Metab.91(12), 4836–4841 (2006).
   PubMed Web of Science ®Google Scholar
• Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J. Endocrinol.197(1), 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• Zheng B, Ohkawa S, Li H, Roberts-Wilson TK, Price SR. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J.24(8), 2660–2669 (2010).
   PubMedGoogle Scholar
• Gilson H, Schakman O, Combaret L et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology148(1), 452–460 (2007).
   PubMed Web of Science ®Google Scholar
• Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer93(4), 425–434 (2005).
   PubMed Web of Science ®Google Scholar
• Russell ST, Wyke SM, Tisdale MJ. Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal.18(7), 1087–1096 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol.298(5), H1565–H1570 (2010).
   PubMed Web of Science ®Google Scholar
• Brink M, Price SR, Chrast J et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology142(4), 1489–1496 (2001).
   PubMedGoogle Scholar
• Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachex. Sarcopenia Muscle1(1), 9–21 (2010).
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Zinc-α2-glycoprotein in cachexia and obesity. Curr. Opin. Support Palliat. Care3(4), 288–293 (2009).
   PubMedGoogle Scholar
• Schweiger M, Schreiber R, Haemmerle G et al. Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. J. Biol. Chem.281(52), 40236–40241 (2006).
   PubMed Web of Science ®Google Scholar
• Bing C, Russell S, Becket E et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer95(8), 1028–1037 (2006).
   PubMed Web of Science ®Google Scholar
• Dahlman I, Mejhert N, Linder K et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br. J. Cancer102(10), 1541–1548 (2010).
   PubMed Web of Science ®Google Scholar
• Ryden M, Agustsson T, Laurencikiene J et al. Lipolysis – not inflammation, cell death, or lipogenesis – is involved in adipose tissue loss in cancer cachexia. Cancer113(7), 1695–1704 (2008).
   PubMed Web of Science ®Google Scholar
• Drott C, Persson H, Lundholm K. Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin. Physiol.9(5), 427–439 (1989).
   PubMedGoogle Scholar
• Agustsson T, Ryden M, Hoffstedt J et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res.67(11), 5531–5537 (2007).
   PubMed Web of Science ®Google Scholar
• Islam-Ali B, Khan S, Price SA, Tisdale MJ. Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br. J. Cancer85(5), 758–763 (2001).
   PubMed Web of Science ®Google Scholar
• Ishiko O, Yasui T, Hirai K et al. Lipolytic activity of anemia-inducing substance from tumor-bearing rabbits. Nutr. Cancer33(2), 201–205 (1999).
   PubMed Web of Science ®Google Scholar
• Groundwater P, Beck SA, Barton C, Adamson C, Ferrier IN, Tisdale MJ. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br. J. Cancer62(5), 816–821 (1990).
   PubMedGoogle Scholar
• Felix K, Fakelman F, Hartmann D et al. Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci.88(5–6), 218–225 (2011).
   PubMedGoogle Scholar
• Todorov PT, Mcdevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res.58(11), 2353–2358 (1998).
   PubMedGoogle Scholar
• Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc α-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin. Cancer Res.7(4), 846–853 (2001).
   PubMed Web of Science ®Google Scholar
• Irmak S, Tilki D, Heukeshoven J et al. Stage-dependent increase of orosomucoid and zinc-α2-glycoprotein in urinary bladder cancer. Proteomics5(16), 4296–4304 (2005).
   PubMed Web of Science ®Google Scholar
• Bing C, Bao Y, Jenkins J et al. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl Acad. Sci. USA101(8), 2500–2505 (2004).
   PubMed Web of Science ®Google Scholar
• Mracek T, Stephens NA, Gao D et al. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer104(3), 441–447 (2011).
   PubMed Web of Science ®Google Scholar
• Russell ST, Zimmerman TP, Domin BA, Tisdale MJ. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-α2-glycoprotein. Biochim. Biophys. Acta1636(1), 59–68 (2004).
   PubMed Web of Science ®Google Scholar
• Russell ST, Tisdale MJ. The role of glucocorticoids in the induction of zinc-α2-glycoprotein expression in adipose tissue in cancer cachexia. Br. J. Cancer92(5), 876–881 (2005).
   PubMedGoogle Scholar
• Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, Van Hall G. Tumor necrosis factor-α modulates human in vivo lipolysis. J. Clin. Endocrinol. Metab.93(2), 543–549 (2008).
   PubMed Web of Science ®Google Scholar
• Bezaire V, Mairal A, Anesia R, Lefort C, Langin D. Chronic TNFα and cAMP pre-treatment of human adipocytes alter HSL, ATGL and perilipin to regulate basal and stimulated lipolysis. FEBS Lett.583(18), 3045–3049 (2009).
   PubMed Web of Science ®Google Scholar
• Ryden M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A, Arner P. Targets for TNF-α-induced lipolysis in human adipocytes. Biochem. Biophys. Res. Commun.318(1), 168–175 (2004).
   PubMed Web of Science ®Google Scholar
• Laurencikiene J, Van Harmelen V, Arvidsson Nordstrom E et al. NF-κB is important for TNF-α-induced lipolysis in human adipocytes. J. Lipid. Res.48(5), 1069–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS. Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes51(10), 2929–2935 (2002).
   PubMed Web of Science ®Google Scholar
• Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science274(5295), 2100–2103 (1996).
   PubMed Web of Science ®Google Scholar
• Jove M, Laguna JC, Vazquez-Carrera M. Agonist-induced activation releases peroxisome proliferator-activated receptor β/δ from its inhibition by palmitate-induced nuclear factor-κB in skeletal muscle cells. Biochim. Biophys. Acta1734(1), 52–61 (2005).
   PubMed Web of Science ®Google Scholar
• Hauner H, Petruschke T, Russ M, Rohrig K, Eckel J. Effects of tumour necrosis factor α (TNF α) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia38(7), 764–771 (1995).
   PubMed Web of Science ®Google Scholar
• Hammarstedt A, Isakson P, Gustafson B, Smith U. Wnt-signaling is maintained and adipogenesis inhibited by TNFα but not MCP-1 and resistin. Biochem. Biophys. Res. Commun.357(3), 700–706 (2007).
   PubMedGoogle Scholar
• Cawthorn WP, Heyd F, Hegyi K, Sethi JK. Tumour necrosis factor-α inhibits adipogenesis via a β-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ.14(7), 1361–1373 (2007).
   PubMed Web of Science ®Google Scholar
• Itoigawa Y, Kishimoto KN, Sano H, Kaneko K, Itoi E. Molecular mechanism of fatty degeneration in rotator cuff muscle with tendon rupture. J. Orthop. Res.29(6), 861–866 (2011).
   PubMedGoogle Scholar
• Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.294(2), R393–R401 (2008).
   PubMed Web of Science ®Google Scholar
• Hardardottir I, Doerrler W, Feingold KR, Grunfeld C. Cytokines stimulate lipolysis and decrease lipoprotein lipase activity in cultured fat cells by a prostaglandin independent mechanism. Biochem. Biophys. Res. Commun.186(1), 237–243 (1992).
   PubMed Web of Science ®Google Scholar
• Bing C, Trayhurn P. New insights into adipose tissue atrophy in cancer cachexia. Proc. Nutr. Soc.68(4), 385–392 (2009).
   PubMed Web of Science ®Google Scholar
• Henderson JT, Mullen BJ, Roder JC. Physiological effects of CNTF-induced wasting. Cytokine8(10), 784–793 (1996).
   PubMedGoogle Scholar
• Ding Q, Mracek T, Gonzalez-Muniesa P et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology150(4), 1688–1696 (2009).
   PubMed Web of Science ®Google Scholar
• Zuijdgeest-Van Leeuwen SD, Van Den Berg JW, Wattimena JL et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism49(7), 931–936 (2000).
   PubMedGoogle Scholar
• Laurencikiene J, Stenson BM, Arvidsson Nordstrom E et al. Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res.68(22), 9247–9254 (2008).
   PubMedGoogle Scholar
• Busquets S, Serpe R, Sirisi S et al. Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. Clin. Nutr.29(6), 733–737 (2010).
   PubMedGoogle Scholar
• Yeh SS, Marandi M, Thode HC Jr et al. Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia. J. Ren. Nutr.20(1), 52–62 (2010).
   PubMedGoogle Scholar
• Couluris M, Mayer JL, Freyer DR, Sandler E, Xu P, Krischer JP. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. J. Pediatr. Hematol. Oncol.30(11), 791–797 (2008).
   PubMedGoogle Scholar
• Strasser F, Luftner D, Possinger K et al. Comparison of orally administered cannabis extract and δ-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, Phase 3, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-cachexia-study-group. J. Clin. Oncol.24(21), 3394–3400 (2006).
   PubMed Web of Science ®Google Scholar
• Weyermann P, Dallmann R, Magyar J et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One4(3), e4774 (2009).
   PubMed Web of Science ®Google Scholar
• Akamizu T, Kangawa K. Ghrelin for cachexia. J. Cachexia Sarcopenia Muscle1(2), 169–176 (2010).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Moriya J, Yasumura Y et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation110(24), 3674–3679 (2004).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Itoh T, Murakami S et al. Treatment of cachexia with ghrelin in patients with COPD. Chest128(3), 1187–1193 (2005).
   PubMed Web of Science ®Google Scholar
• Kung T, Springer J, Doehner W, Anker SD, Von Haehling S. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia conference. Exp. Opin. Investig. Drugs19(4), 579–585 (2010).
   PubMedGoogle Scholar
• Lundholm K, Gunnebo L, Korner U et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer116(8), 2044–2052 (2010).
   PubMed Web of Science ®Google Scholar
• Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an ω-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst. Rev.1, CD004597 (2007).
   Google Scholar
• Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J.407(1), 113–120 (2007).
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos. Int.20(2), 315–322 (2009).
   PubMed Web of Science ®Google Scholar
• Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine32(5), 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Beijer S, Hupperets PS, Van Den Borne BE et al. Effect of adenosine 5’-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs20(7), 625–633 (2009).
   PubMedGoogle Scholar
• Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ. Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag. Res.2, 27–38 (2010).
   PubMedGoogle Scholar
• Silverio R, Laviano A, Rossi Fanelli F, Seelaender M. l-carnitine and cancer cachexia: clinical and experimental aspects. J. Cachex. Sarcopenia Muscle2(1), 37–44 (2011).
   PubMedGoogle Scholar
• Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut54(4), 540–545 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkes EA, Selby AL, Cole AT, Freeman JG, Rennie MJ, Khan ZH. Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur. J. Cancer Care20(5), 593–600 (2011).
   PubMed Web of Science ®Google Scholar
• Steffen BT, Lees SJ, Booth FW. Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. J. Appl. Physiol.105(6), 1950–1958 (2008).
   PubMedGoogle Scholar
• Goldberg RM, Loprinzi CL, Mailliard JA et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol.13(11), 2856–2859 (1995).
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Madeddu C et al. Phase 2 nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med.88(1), 85–92 (2010).
   PubMed Web of Science ®Google Scholar
• Figueras M, Busquets S, Carbo N et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett.569(1–3), 201–206 (2004).
   PubMed Web of Science ®Google Scholar
• Chasen M, Hirschman SZ, Bhargava R. Phase 2 study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J. Am. Med. Dir. Assoc.12(1), 62–67 (2011).
   PubMed Web of Science ®Google Scholar
• Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet361(9363), 1077–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Smart NA, Steele M. The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review. Congest. Heart Fail.17(3), 110–114 (2011).
   PubMedGoogle Scholar
• Janaudis-Ferreira T, Hill K, Goldstein RS et al. Resistance arm training in patients with COPD: a randomized controlled trial. Chest139(1), 151–158 (2011).
   PubMed Web of Science ®Google Scholar
• Troosters T, Probst VS, Crul T et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.181(10), 1072–1077 (2010).
   PubMed Web of Science ®Google Scholar
• Lemmey AB, Marcora SM, Chester K, Wilson S, Casanova F, Maddison PJ. Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum.61(12), 1726–1734 (2009).
   PubMedGoogle Scholar
• Dong J, Sundell MB, Pupim LB, Wu P, Shintani A, Ikizler TA. The effect of resistance exercise to augment long-term benefits of intradialytic oral nutritional supplementation in chronic hemodialysis patients. J. Ren. Nutr.21(2), 149–159 (2011).
   PubMedGoogle Scholar
• Murphy KT, Koopman R, Naim T et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J.24(11), 4433–4442 (2010).
   PubMed Web of Science ®Google Scholar
• Morine KJ, Bish LT, Pendrak K, Sleeper MM, Barton ER, Sweeney HL. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One5(2), e9176 (2010).
   Google Scholar
• Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr.83(6), 1345–1350 (2006).
   PubMed Web of Science ®Google Scholar
• Mak RH, Cheung WW, Zhan JY, Shen Q, Foster BJ. Cachexia and protein-energy wasting in children with chronic kidney disease. Pediatr. Nephrol. doi:10.1007/s00467-011-1765-5 (2011) (Epub ahead of print).
   Google Scholar
• Gullett NP, Mazurak VC, Hebbar G, Ziegler TR. Nutritional interventions for cancer-induced cachexia. Curr. Probl. Cancer35(2), 58–90 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhou Y, Wu L et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann. Clin. Lab Sci.38(2), 113–119 (2008).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Horwich TB, Oreopoulos A et al. Risk factor paradox in wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care10(4), 433–442 (2007).
   PubMed Web of Science ®Google Scholar